Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer

Phase 3

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: FOLFOX
Biological: Pegilodecakin

First Posted Date: 2016-10-05

Last Posted Date: 2020-10-19

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 567

Registration Number: NCT02923921

Locations: 🇺🇸
Texas Oncology - San Antonio Medical Center, San Antonio, Texas, United States
🇺🇸
Virginia Piper Cancer Institute, Minneapolis, Minnesota, United States
🇺🇸
Sarah Cannon Research Institute SCRI, Nashville, Tennessee, United States

and more 127 locations

A Study of Abemaciclib (LY2835219) in Native Chinese Participants With Advanced and/or Metastatic Cancers

Phase 1

Completed

Conditions: Advanced Cancer
Metastatic Cancer

Interventions: Drug: Abemaciclib

First Posted Date: 2016-09-29

Last Posted Date: 2020-09-25

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 26

Registration Number: NCT02919696

Locations: 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shanghai, China

A Study of the Absorption, Distribution, Metabolism and Excretion of LY3039478 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY3039478

First Posted Date: 2016-09-28

Last Posted Date: 2017-01-10

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 8

Registration Number: NCT02917733

Locations: 🇺🇸
Covance Clinical Research Inc, Madison, Wisconsin, United States

A Study of LY3337641 in Healthy Male Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: [¹⁴C]-LY3337641

First Posted Date: 2016-09-26

Last Posted Date: 2023-08-25

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 6

Registration Number: NCT02914379

Locations: 🇺🇸
Covance Clinical Research Unit, Madison, Wisconsin, United States

Study of LY3039478 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY3039478
Drug: 3C 15N 2H-LY3039478 IV

First Posted Date: 2016-09-20

Last Posted Date: 2017-01-25

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 12

Registration Number: NCT02906618

Locations: 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Leeds, United Kingdom

A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Plaque Psoriasis

Phase 2

Completed

Conditions: Plaque Psoriasis

Interventions: Drug: Placebo
Drug: Mirikizumab

First Posted Date: 2016-09-14

Last Posted Date: 2020-06-18

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 205

Registration Number: NCT02899988

Locations: 🇺🇸
Renstar Medical Research, Ocala, Florida, United States
🇺🇸
Forward Clinical Trials, Inc, Tampa, Florida, United States
🇵🇷
Grupo Dermatologico de Carolina, Carolina, Puerto Rico

and more 13 locations

A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer

Phase 3

Completed

Conditions: Gastroesophageal Junction Adenocarcinoma
Gastric Adenocarcinoma

Interventions: Drug: Ramucirumab
Drug: Placebo
Drug: Paclitaxel

First Posted Date: 2016-09-13

Last Posted Date: 2022-06-14

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 440

Registration Number: NCT02898077

Locations: 🇲🇾
University Malaya Medical Centre, Kuala Lumpur, Malaysia
🇲🇾
National Cancer Institute, Wilayah Persekutuan, Malaysia
🇹🇭
Rajavithi Hospital, Bangkok, Ratchathewi District, Thailand

and more 29 locations

A Study of LY3041658 in Participants With Skin Diseases

Phase 1

Completed

Conditions: Skin Diseases
Psoriasis

Interventions: Drug: LY3041658
Drug: Placebo

First Posted Date: 2016-09-12

Last Posted Date: 2019-05-03

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 60

Registration Number: NCT02896868

Locations: 🇺🇸
Parexel Early Phase Unit at Glendale, Glendale, California, United States
🇺🇸
Dawes Fretzin Clinical Research, Indianapolis, Indiana, United States
🇺🇸
PAREXEL-Phase 1 Baltimore Harbor Hospital Center, Baltimore, Maryland, United States

and more 2 locations

A Study of Mirikizumab (LY3074828) in Participants With Active Crohn's Disease

Phase 2

Completed

Conditions: Crohn's Disease

Interventions: Drug: Placebo
Drug: Mirikizumab

First Posted Date: 2016-09-07

Last Posted Date: 2022-08-30

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 191

Registration Number: NCT02891226

Locations: 🇺🇸
Digestive Healthcare of Georgia, Atlanta, Georgia, United States
🇺🇸
Virginia Mason Medical Center, Seattle, Washington, United States
🇺🇸
University of Washington Medical Center, Seattle, Washington, United States

and more 105 locations

A Study of the Effect of Abemaciclib on Metformin and Iohexol in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Metformin
Drug: Abemaciclib
Drug: Iohexol
Drug: Placebo

First Posted Date: 2016-08-30

Last Posted Date: 2019-01-04

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 40

Registration Number: NCT02884089

Locations: 🇺🇸
Dallas Clinical Research Unit, Dallas, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy